Centessa Pharmaceuticals plc American Depositary Receipt (260)
XMUN 
Summary
260 Chart
Options Traders Pick Up Pharma Stock After Eli Lilly Buyout
Centessa Pharmaceuticals PLC (NASDAQ:CNTA) shares are surging today, last seen 44.4% higher to trade at $39.90 on news that Eli Lilly (LLY) will acquire the company for $6.3 billion.
Eli Lilly stock rises after $7.8B Centessa deal—bet on sleep drugs
Eli Lilly has agreed to acquire Centessa Pharmaceuticals in a deal valued at up to $7.8 billion, marking a significant expansion of the drugmaker's neuroscience portfolio into sleep medicine. Under the terms announced Tuesday, Lilly will pay $38 per share in cash upfront, valuing Centessa at approximately $6.3 billion.
Eli Lilly to Buy Centessa Pharmaceuticals for Initial $6.3 Billion
Eli Lilly has agreed to buy clinical-stage company Centessa Pharmaceuticals for an initial $6.3 billion in a deal that expands the drugmaker's neuroscience portfolio and capabilities into sleep medicine.
Centessa Pharmaceuticals plc American Depositary Receipt (260) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Centessa Pharmaceuticals plc American Depositary Receipt ever had a stock split?
Centessa Pharmaceuticals plc American Depositary Receipt Profile
| Biotechnology Industry | Healthcare Sector | Mario Alberto Accardi CEO | XMUN Exchange | US1523091007 ISIN |
| GB Country | 77 Employees | 24 Jun 2026 Last Dividend | - Last Split | - IPO Date |
Overview
Centessa Pharmaceuticals plc is a burgeoning clinical-stage pharmaceutical entity committed to the discovery, development, and delivery of innovative medicines aimed at addressing the needs of patients. Incorporated in 2020, this company is setting its sights on pioneering advancements in medical science from its headquarters in Altrincham, United Kingdom. With a robust dedication to innovating healthcare solutions, Centessa Pharmaceuticals is navigating the complex landscape of drug development with an impressive array of products in its pipeline, focusing on a variety of therapeutic areas.
Products and Services
- SerpinPC: This activated protein C inhibitor is being developed with the aim of treating hemophilia A and B, a significant leap forward in managing these challenging bleeding disorders. By potentially offering a novel mechanism of action, SerpinPC represents a promising therapeutic option for patients suffering from these genetic disorders.
- ORX750: An orally administered OX2R agonist, ORX750 is designed to cater to the needs of patients with narcolepsy and other sleep disorders. Its mechanism targets the orexin receptor-2, aiming to balance sleep-wake cycles in patients, providing a much-needed treatment option in the realm of sleep medicine.
- LB101: As a bi-specific monoclonal antibody, LB101 (PD-L1xCD47 LockBody) is at the forefront of oncological innovation. It's engineered to selectively drive potent effector function activity of CD47 and CD3, while meticulously avoiding systemic toxicity. This strategic approach to cancer treatment holds the promise of addressing solid tumors with a tailored and potent therapeutic.
- OX2R Agonists: Beyond ORX750, Centessa is developing a suite of compounds targeting the OX2R pathway, with a focus on unlocking new treatment avenues for narcolepsy. These compounds are in various stages of development, underscoring the company's dedication to expanding its portfolio in sleep disorder therapies.
- Earlier-stage preclinical and discovery-stage programs: In its bid to widen the therapeutic landscape, Centessa Pharmaceuticals is also focusing on the development of earlier-stage preclinical assets and discovery-stage programs. These efforts underscore the company’s commitment to pioneering future medical advancements, laying the groundwork for a new era of healthcare solutions.
